background thrombolytic therapy in patients with sub-massive pulmonary embolism (smpte) needs further assessment. objectives the current study aimed to assess a potential benefit of thrombolytic and non-thrombolytic therapy in patients with smpte. patients and methods one hundred-nineteen patients were enrolled with smpte from 2006 to 2010 in the tertiary care center of rajaie medical and resea...

right-sided heart thrombus is a life-threatening condition that necessitates immediate therapy. detection of right-sided heart thrombus is usually via transthoracic echocardiography. generally, thrombolysis is considered a treatment of choice, but there is currently no consensus about the optimal therapeutic choice. we present a case of multiple right atrial thrombi with concurrent mobile and b...

background: the use of thrombolytic agents in the treatment of hemodynamically stable patients with acute submassive pulmonary embolism (pte) remains controversial. we, therefore, conducted this study to compare the effect of thrombolytic plus anticoagulation versus anticoagulation alone on early death and adverse outcome following submassive pte. methods: w e conducted a study of patients with...

background: thrombolytic therapy is the only approved treatment for acute cerebral ischemia. the hemorrhagic transformation is the greatest complication of this treatment, which may occur after recanalization of occluded artery. the aim of this study was to determine factors associated with clinical improvement and worsening in patients with acute ischemic stroke treated with intravenous thromb...

0

background: we sought to evaluate the efficacy and safety of the different trade forms of streptokinase available in our country, namely heberkinasa (heberbiotec, havana, cuba) and streptase (aventis behring gmbh, marburg, germany). methods: we conducted a double-blind randomized clinical trial to compare the two streptokinase formulations, i.e. heberkinasa (hbk) or streptase (stp), in patients...

conclusions: the major barriers for thrombolytic therapy for patients with ais in this setting were delays in the provision of in-hospital services, like initial patient assessment, ct scans or laboratory studies. these results were in contrast with previous reports. background: intravenous thrombolysis is an approved treatment method for patients with acute ischemic stroke (ais) and is recomme...

stroke is an important cause of disability and death worldwide, with the majority of strokes occurring in older people. thrombolysis with recombinant tissue plasminogen activator (r-tpa) is the approved treatment for acute ischemic stroke. a major concern of physicians, who treat acute ischemic stroke with recombinant tissue plasminogen activator (r-tpa,) is the risk of intracerebral hemorrhage...

introduction: the precise time of using percutaneous coronary intervention (pci) after fibrinolytic therapy for maximum efficiency and minimum side effects is still undetermined. therefore, the present study was designed to compare the outcome of myocardial infarction (mi) patients who underwent surgical intervention (angiography and pci) within 48 hours of thrombolytic therapy or after that. m...